A new trading day began on Friday, with Kymera Therapeutics Inc (NASDAQ: KYMR) stock price down -8.67% from the previous day of trading, before settling in for the closing price of $45.94. KYMR’s price has ranged from $16.94 to $53.27 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 241.22%. Meanwhile, its annual earnings per share averaged 0.66%. With a float of $54.85 million, this company’s outstanding shares have now reached $55.59 million.
Let’s determine the extent of company efficiency that accounts for 187 employees. In terms of profitability, gross margin is 92.85%, operating margin of -223.0%, and the pretax margin is -191.26%.
Kymera Therapeutics Inc (KYMR) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Kymera Therapeutics Inc is 9.94%, while institutional ownership is 93.74%. The most recent insider transaction that took place on Sep 17 ’24, was worth 651,766. In this transaction Director of this company sold 13,500 shares at a rate of $48.28, taking the stock ownership to the 0 shares. Before that another transaction happened on Sep 17 ’24, when Company’s Director proposed sale 13,500 for $48.48, making the entire transaction worth $654,480.
Kymera Therapeutics Inc (KYMR) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 0.66% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.90% during the next five years compared to -39.18% drop over the previous five years of trading.
Kymera Therapeutics Inc (NASDAQ: KYMR) Trading Performance Indicators
Here are Kymera Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.55. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 28.34.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.33, a number that is poised to hit -0.77 in the next quarter and is forecasted to reach -2.79 in one year’s time.
Technical Analysis of Kymera Therapeutics Inc (KYMR)
Looking closely at Kymera Therapeutics Inc (NASDAQ: KYMR), its last 5-days average volume was 0.44 million, which is a drop from its year-to-date volume of 0.59 million. As of the previous 9 days, the stock’s Stochastic %D was 18.88%. Additionally, its Average True Range was 2.64.
During the past 100 days, Kymera Therapeutics Inc’s (KYMR) raw stochastic average was set at 52.93%, which indicates a significant increase from 3.92% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.86% in the past 14 days, which was lower than the 66.04% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $47.17, while its 200-day Moving Average is $40.71. However, in the short run, Kymera Therapeutics Inc’s stock first resistance to watch stands at $44.44. Second resistance stands at $46.92. The third major resistance level sits at $48.39. If the price goes on to break the first support level at $40.49, it is likely to go to the next support level at $39.02. Now, if the price goes above the second support level, the third support stands at $36.54.
Kymera Therapeutics Inc (NASDAQ: KYMR) Key Stats
With a market capitalization of 2.48 billion, the company has a total of 64,765K Shares Outstanding. Currently, annual sales are 78,590 K while annual income is -146,960 K. The company’s previous quarter sales were 3,740 K while its latest quarter income was -62,490 K.
